Profiling with senescence-associated secretory phenotype score identifies GDC-0879 as a small molecule sensitizing glioblastoma to anti-PD1



Summary

Glioblastoma (GBM) is a deadly brain cancer with limited treatment options, and immunotherapy’s effectiveness is often hindered. This research explores a new strategy by targeting cellular senescence, a state of irreversible cell cycle arrest, in GBM. They developed a senescence-associated secretory phenotype (SASP) score to profile GBM tumors and identify patients likely to benefit from senolytic drugs. Using this score, they found that the senolytic GDC-0879 can sensitize GBM cells to anti-PD1 immunotherapy. This suggests that targeting senescence, specifically with GDC-0879, could improve immunotherapy outcomes in GBM patients with high SASP scores. The study provides a potential therapeutic avenue for enhancing anti-PD1 efficacy in glioblastoma.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!